The Newborn Metabolic Screening Market To Move Through The Consistency-Oriented Ellipse By Reaching US$ 247 Mn From 2020 to 2030

The Newborn Metabolic Screening Market will witness a CAGR of 9.2%, reaching US$ 247 Mn between 2020 to 2030. With medical IoT implying the use of wearable monitors, devices, and various integrated applications regarding healthcare needs, the healthcare vertical is bound to scale new-fangled heights in the upcoming period. This is what the healthcare vertical would all be in the next 10 years.

Increasing birth rates across the world are expected to drive demand for newborn metabolic screening, as the risk of galactosemia, sickle cell disease, phenylketonuria, maple syrup urine disease, and cystic fibrosis is higher among infants. Various countries are implementing screening for metabolic diseases in newborns as a part of their immunization programs. To remain competitive and ensure a robust product pipeline, leading companies continue to identify potential assets through pilot screening programs, which typically have limited resources to see projects through the market.

According to a latest report published by Persistence Market Research, the global newborn metabolic screening market was valued around US$ 247 Mn in 2020, and is expected to witness an impressive CAGR of over 9% during the forecast period (2020 – 2030).

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/31998

Companies covered in Newborn Metabolic Screening Market Report

• PerkinElmer
• Bio-Rad Laboratories
• Trivitron Healthcare Private Limited
• BioMedomics, Inc.
• Luminex Corporation
• MP BIOMEDICALS
• Synergy Medical Systems LLP
• Agilent Technologies, Inc
• Thermo Fisher Scientific, Inc
• Zivak Technologies

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/31998

 Key Takeaways from Market Study  

• Sickle cell disease is expected to contribute more than 30% of revenue share to the market.
• By sample, blood testing held the highest market share in 2019 due to efficient diagnostic results.
• Europe holds a significant share of over 30% in the global newborn metabolic screening market.
• Leading manufacturers are focused on strengthening their product portfolios and regional expansion through collaborations.
• Hospitals are expected to hold significant market share, due to high number of screening programs being arranged in collaboration with hospitals.
• The COVID-19 outbreak has had a negative impact on the market, as short-term lockdowns disturbed the production and supply chain of kits.
• The market in the U.S is projected to expand at a CAGR of close to 10% through 2030.
• The U.K market has a share of more than 17% in Europe, and is expected to progress at a CAGR of more than 12% over the next ten years.

“Increasing prevalence of new born metabolic diseases and rising adoption of related screening program will boost the global market,” says an analyst of Persistence Market Research.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/31998

Collaborations & Acquisitions Key Strategies amongst Market Players

Leading players in the newborn metabolic screening landscape are focusing on improving their product portfolios through partnerships and acquisitions. Various players are also focusing on regulatory approvals and innovative product launches.

• On October 05, 2020, PerkinElmer announced CE-IVD approval of the EONIS™ newborn screening assay.
• In October 2018, Trivitron’s Labsystems Diagnostics launched high quality newborn screening panels.
• On September 3, 2020, Sickle SCAN® was approved by the Department of Health in Australia.

What Does the Report Cover?

Persistence Market Research offers a unique perspective and actionable insights on the newborn metabolic screening market in its latest study, presenting historical demand assessment of 2015 – 2019 and projections for 2020 – 2030, on the basis of test (galactosemia, sickle cell disease, cystic fibrosis, toxoplasmosis, phenylketonuria (PKU), methylmalonic acidemia, maple syrup urine disease (MSUD), tyrosinemia, citrullinemia, and Medium Chain Acyl CoA Dehydrogenase (MCAD) Deficiency), sample (blood and urine), and end user (diagnostic laboratories, specialty clinics, and hospitals), across seven key regions of the world.

Access Related Reports- 

Animal Drug Compounding Market @ https://www.prnewswire.com/news-releases/animal-drug-compounding-market-is-set-to-witness-healthy-growth-at-a-cagr-of-8-over-the-forecast-period-of-2021-2031-persistence-market-research-301307646.html